GSK closing Costa Rica consumer products plant, cutting 62 jobs

GlaxoSmithKline will be closing a manufacturing plant in San Jose, Costa Rica over the next three years.

GlaxoSmithKline is giving up on manufacturing in Costa Rica and will wind down operations at its consumer health products plant in San Jose over the next three years. The move will cost more than 60 people their jobs.

The U.K. drugmaker last week announced that it intends to close the plant in San Jose by the end of 2019 after moving production to other facilities in Latin America, according to a translated story in El Financiero. 

According to a GSK spokesperson, the site which has been producing products for more than 60 years has about 150 employees, but only 62 are expected to lose their jobs. GSK will move manufacturing and packaging of the soluble effervescent antacid brands Eno and Andrews and the acetaminophen pain drug Panadol to other “appropriate” sites. 


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

A release forwarded by GSK said the move will not affect the availability of the company’s products in the country in any way.

GSK said the decision will not affect its Pharmaceutical and Consumer Healthcare divisions or its Business Services Center in the country, which employ about 500 people. The Business Services Center is actually expected to add jobs in coming months.

While losing production jobs, Costa Rica will also be the beneficiary of some administrative jobs from AstraZeneca. In December, the U.K.-based company said it would downsize a finance division in Alderley Park, England, and move an undisclosed number of positions to centralized facilities in Malaysia, Poland and Costa Rica.  

Suggested Articles

Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.

WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.